Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results

• Published in: European clinical respiratory journal Vol. 3; no. 1; p. 32608
• Main Authors: Salih, Goran Nadir, Shaker, Saher Burhan, Madsen, Helle Dall, Bendstrup, Elisabeth
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2016; Co-Action Publishing; Taylor & Francis Group
• Subjects: efficacy; idiopathic pulmonary fibrosis; Original; pirfenidone; safety; therapy; idiopathic pulmonary fibrosis; pirfenidone; safety; therapy; efficacy
• ISSN: 2001-8525; 2001-8525
• DOI: 10.3402/ecrj.v3.32608

Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF). To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to target population, safety, adherence to the treatment and effect analysis in a well-characterised IPF population in a real-life setting. Retrospective data collection from medical records of all patients in Denmark with IPF from 2011 to 2014. Data included baseline demographics, high-resolution computed tomography (HRCT), histopathology, forced vital capacity (FVC) and 6-min walk test (6MWT). Longitudinal data on FVC, walk test, adherence to the treatment and vital status were also collected. Pirfenidone treatment was initiated in 113 patients. Mean age was 69.6±8.1 years (±SD), and 71% were male. Definite IPF diagnosis required thoracoscopic lung biopsy in 45 patients (39.8%). The remaining 68 cases had a definite (64 patients) or possible usual interstitial pneumonia (four patients) pattern on HRCT. Patients were followed for 0.1-33.8 months (median 9.4 months). Fifty-one patients (45.2%) needed dose adjustment, 18 (16%) patients discontinued therapy and 13 patients (11.5%) died. The annual mean decline in FVC was 164 ml (SE 33.2). The decline in 6MWT was 18.2 m (SE 11.2). Nausea (44.2%), fatigue (38.9%) and skin reactions (32.7%) were frequent adverse events. Patients with IPF treated with pirfenidone experienced tolerable adverse events. Patients were maintained on treatment due to a careful follow-up and dose adjustment programme. The annual decline in physiological parameters and mortality rate was comparable to previous randomised controlled trials.